Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. - Wikidata - awgldk - TriplyDB

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.

http://www.wikidata.org/entity/Q39778685

about

Linkers Having a Crucial Role in Antibody-Drug Conjugates Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems Antibody Drug Conjugates: Preclinical Considerations A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma A mechanistic tumor penetration model to guide antibody drug conjugate design IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Linked-in: design and efficacy of antibody drug conjugates in oncology Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models Investigational antibody drug conjugates for solid tumors.Designing immunoconjugates for cancer therapy.Pharmacokinetic considerations for antibody drug conjugates.Advances in targeted therapeutic agents.Drug-conjugated antibodies for the treatment of cancer.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.Receptor-targeted drug delivery: current perspective and challenges.Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay.Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.Strategies and challenges for the next generation of antibody-drug conjugates.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation.Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability.New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting.Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates.Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates.Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.

P2860

Q26752763-E0CD34E2-EE91-48DD-9045-BB4103E499DD Q26782485-029EA8BD-D819-4886-AB81-579ED21B0CFC Q27022321-31932B5C-0CDD-4B89-A00D-84DBB8F825DB Q28487973-BE5364A2-DF1E-4270-996A-83A623B5A12E Q28544636-3DDCF9BC-2BB8-49FF-9EDF-357EEA5F6225 Q28660580-55E19B00-6097-46B0-99F9-8B2838D2E641 Q30496972-E783BC90-4B0C-4DF6-A048-7CF5B32F0152 Q30524836-B4FD5FEC-BA46-4C06-8F15-1758809851E0 Q33873317-3F099730-476F-46B5-807F-75827EB8E55E Q34655256-30FC6F4C-AF11-4EA9-AD9E-8370B3920E0D Q34660299-99B8BABE-1F95-4C1E-B4EF-52C813D589F6 Q35459059-AA2E712E-BF6F-4FFA-B86B-3CC547852032 Q35892045-284EA387-320C-4B0C-A080-48468998CAFF Q37029370-1F60EBF5-E994-4A5D-BC68-FC4CF969F73B Q37447340-ABDC2704-1CF5-4135-B2D9-43AAEBB55B00 Q37877745-639CCB2C-D058-4CC6-B580-B9F767570577 Q38017203-8271C567-2B6D-4B87-93EB-9567B75D3782 Q38022192-0D776FC7-C4D5-4CF7-A843-B1365AE3F014 Q38029122-87AB85DB-9915-45D3-AE9D-15BBEED517A5 Q38061647-637C0535-4B4D-4BC4-9BD0-910A57058CA5 Q38068494-651A9627-AC1B-45D5-B86F-AE691AB95114 Q38092648-D5A200A2-2B0A-4BF9-9B49-5132BDA7D188 Q38202691-A4639AAB-2F90-494A-BF82-63D72B63FC6D Q38265617-376B7FB0-7ACD-43D3-BC8A-9F8360842D34 Q38453769-30A162A9-6F32-4CC1-B7F1-E52B4D005EA4 Q38579129-51354874-A558-4DA4-8643-D4C44FF040AB Q38624597-DCF20AD2-ECC8-4617-9A14-7C85D3E75E5E Q38648690-180EBDB3-6E9B-48ED-8A21-F7180BC05002 Q38915595-83F38D51-8231-42EA-8280-9DB398BE3BA0 Q38960075-A931B3D3-704C-4CF4-BFA2-E459481B2CE6 Q39182945-C41862BD-5CAB-4A9D-B28C-EE8BE29CFF5C Q39210427-993C7D22-121C-46A8-8469-11056844F632 Q39427630-070624DA-F1A4-4128-8AD0-C16CF70E889A Q39645683-5872752D-7AF9-410D-B753-133BC269B76D Q39815639-E3785382-2AA1-4661-98A4-EA1419A3076F Q40416482-D713577B-FA57-44B6-9D5D-8709BAA062A6 Q41282870-38329C30-C726-44FD-90FC-A862B9F490EC Q42314398-FE9990E8-ACD4-4561-A47C-BD083CB64D7B Q43751494-978D30FB-C3AA-4FCA-9CAB-8DB5EAE58834 Q46871150-007031A2-5745-48C4-92CB-17E1C96F19B9

P2860

Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.

http://www.wikidata.org/entity/Q39778685

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.

@en

Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.

@nl

type

label

Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.

@en

Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.

@nl

prefLabel

Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.

@en

Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.

@nl

P1433

Q39778685-C31B5231-CB8F-4E02-BD39-29E94B8E3146

P1476

Q39778685-3B7D79CB-7968-42F0-BA30-F7288B5F2E02

P2093

Q39778685-21153E63-7D6F-4DB1-8612-98B224AB1E4B

Q39778685-59FB9677-5694-4B7D-9EB4-38F8227A2738

Q39778685-628CCFFB-8219-4FA2-95EE-36E896E89FD8

Q39778685-69100B16-6AC4-44FD-AB64-25317A77D549

Q39778685-80656BF6-B278-41C4-8AD1-EE604C094A52

Q39778685-9121CC94-2565-4337-90B4-6B92B49CD500

Q39778685-B05F28C3-DAD6-47B7-815E-7279B5205452

P304

Q39778685-A2F4D6B7-5DC4-48D5-BF3C-0624AFF04F95

P31

Q39778685-77A5EC31-FC2B-4ECD-B126-FB567FE8DD01

P356

Q39778685-6E9BD9CE-1E9A-44A9-A7FF-F1F7E755F78C

P433

Q39778685-849B8735-4011-4C35-8844-C369E040A851

P478

Q39778685-C539C403-9D68-4980-8A2A-2308D412559B

P577

Q39778685-C59C4A23-FA57-4457-8E12-F2E0F1F66F72

P5875

Q39778685-EDF7874C-0767-46A2-B34F-9B4FCF5C45FC

P698

Q39778685-0258936B-AAE5-4C58-8E01-07BE08045684

P921

Q39778685-10B8C4C6-EF32-4F6F-B071-AAA2E37D8C41

P356

P1433

Bioconjugate Chemistry

P1476

Tumor delivery and in vivo pro ...... ibody-maytansinoid conjugates.

@en

P2093

Charlene Audette

http://www.w3.org/2001/XMLSchema#string

Hans K Erickson

http://www.w3.org/2001/XMLSchema#string

Kathleen Whiteman

http://www.w3.org/2001/XMLSchema#string

Michele F Mayo

http://www.w3.org/2001/XMLSchema#string

Rajeeva Singh

http://www.w3.org/2001/XMLSchema#string

Sharon D Wilhelm

http://www.w3.org/2001/XMLSchema#string

Wayne C Widdison

http://www.w3.org/2001/XMLSchema#string

P304

84-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/BC900315Y

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38069017

http://www.w3.org/2001/XMLSchema#string

P698

19891424

http://www.w3.org/2001/XMLSchema#string

P921